Idiopathic pulmonary fibrosis – Basic Information

Go back

Idiopathic pulmonary fibrosis is a serious chronic lung disease where the tissue around the air sacs becomes thick, stiff, and permanently scarred for reasons that remain unknown, making it progressively harder to breathe and affecting quality of life over time.

Understanding Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis, commonly known as IPF, is a condition where the lungs become damaged by scar tissue that builds up over time. The word “idiopathic” means that doctors cannot identify a clear cause for why this happens. The word “fibrosis” refers to scarring. This scarring affects the tissue that surrounds the tiny air sacs in your lungs, called alveoli, which are the small pockets where oxygen enters your bloodstream and carbon dioxide leaves it.[1]

When lung tissue becomes thick and stiff, it cannot expand and contract as it should. This makes it difficult for oxygen to pass through the lung walls into the blood. As the scarring gets worse, people with IPF find themselves struggling to catch their breath, even during simple daily activities that never felt difficult before. The disease is progressive, which means it gradually worsens over time, though the speed at which this happens varies greatly from one person to another.[3]

IPF belongs to a larger family of more than 200 conditions called interstitial lung diseases, or ILDs. These diseases are characterized by inflammation, scarring, or both, which damage the lung’s ability to absorb oxygen from the air. Among all the types of interstitial lung diseases, IPF is the most common form when the cause is unknown.[2]

There is currently no cure for IPF. The lung damage that has already occurred cannot be reversed or repaired. However, certain treatments and lifestyle changes can help slow down the rate at which scarring progresses, ease symptoms, and improve the overall quality of life for people living with this condition. For some patients, a lung transplant may be considered as a treatment option.[1]

Who Gets Idiopathic Pulmonary Fibrosis

IPF affects around 50,000 people diagnosed each year in the United States. Studies suggest that about 30,000 people are living with IPF in the United Kingdom. Globally, around 5 million people are affected by this disease.[7][8]

The disease is most commonly diagnosed in people who are in their 60s and 70s. It usually develops in individuals around 70 to 75 years old. IPF is rare in people under the age of 50, though it can occur in younger individuals, especially if there is a family history of the disease.[4][7]

Men are affected more often than women. The reasons for this difference are not entirely clear, but it may be related to differences in exposure to environmental factors or occupational hazards over a lifetime.[8]

The disease newly occurs in about 12 per 100,000 people per year. This rate has been increasing in recent years, though it is unclear whether this is due to better diagnosis and awareness or a true increase in the number of cases.[8]

What Causes Idiopathic Pulmonary Fibrosis

The defining feature of IPF is that its cause is unknown. The word “idiopathic” itself means that doctors and researchers cannot pinpoint a specific reason why the disease develops in a particular person. This makes IPF different from other types of pulmonary fibrosis, where the cause can sometimes be identified, such as exposure to certain dusts, medications, or autoimmune diseases.[1]

In people with IPF, the tiny air sacs in the lungs, called alveoli, become damaged. Over time, the tissue around these air sacs becomes thick and stiff, forming scar tissue. This scarring makes it difficult for oxygen to pass through the lung walls into the bloodstream. The lungs lose their ability to expand properly, and breathing becomes increasingly difficult.[4]

Researchers believe that IPF develops when the lungs do not heal properly after some form of damage or inflammation. Instead of normal healing, the repair process goes wrong, leading to an excessive buildup of scar tissue. It is thought that this happens due to a combination of genetic factors and environmental exposures, though no single cause has been identified.[6][7]

The exact process that leads to scarring is complex and involves many changes in the lung cells. Some researchers believe that the cells lining the air sacs become damaged, which triggers a cascade of events involving the immune system, the activation and growth of fibroblasts (cells that produce scar tissue), and the abnormal remodeling of the lung structure.[13]

Risk Factors for Developing IPF

While the exact cause of IPF is unknown, certain factors are known to increase a person’s risk of developing the disease. Understanding these risk factors can help identify people who may be more vulnerable and encourage earlier monitoring and intervention.[1]

Smoking is one of the strongest risk factors for IPF. Cigarette smoking damages the lungs and can trigger abnormal healing processes that lead to scarring. People who smoke or have smoked in the past are at significantly higher risk of developing IPF compared to those who have never smoked.[4][8]

Age is another important risk factor. The risk of IPF increases as people get older. Most people who develop IPF are over the age of 60. This may be because the lungs’ ability to repair themselves declines with age, making older individuals more susceptible to abnormal scarring.[6]

A family history of IPF or pulmonary fibrosis is also a risk factor. Studies estimate that between 5 and 20 percent of people with IPF have a relative who also has the disease. This is known as familial pulmonary fibrosis. Having a family member with IPF suggests that genetic factors may play a role in increasing susceptibility to the disease.[7]

Exposure to certain environmental and occupational substances can increase the risk of IPF. These include dusts from metals, wood, and agricultural work. People who have been exposed to substances like asbestos, silica, or beryllium over long periods are at higher risk. Viral infections have also been suggested as potential triggers, though this connection is not fully understood.[4][6][7]

Gastroesophageal reflux disease, commonly known as GERD, has been linked to IPF, though it is unclear whether GERD contributes to the disease or is simply more common in people with IPF. Some researchers believe that stomach acid reaching the lungs could cause damage that triggers scarring.[8]

Certain genetic conditions, such as dyskeratosis congenita, a rare type of bone marrow failure caused by changes in DNA, can increase the risk of developing pulmonary fibrosis.[6]

⚠️ Important
If you smoke and have been diagnosed with IPF, quitting smoking is one of the most important steps you can take to protect your lungs. Even if you do not have IPF but have risk factors such as a family history of the disease or exposure to lung-damaging substances, avoiding smoking and limiting exposure to harmful dusts or chemicals can reduce your risk.

Recognizing the Symptoms of IPF

The symptoms of IPF tend to develop gradually. In the early stages, many people do not notice any symptoms at all, or they may dismiss their breathlessness as a normal part of aging or being out of shape. As the disease progresses and more scar tissue builds up in the lungs, symptoms become more noticeable and begin to interfere with daily life.[4]

Shortness of breath, also called dyspnea, is the most common symptom of IPF. At first, people may feel breathless only during physical activity, such as climbing stairs or walking uphill. Over time, even light activities like getting dressed or walking around the house can cause significant breathlessness. In advanced stages, some people feel short of breath even when sitting still or resting.[1][3]

A persistent dry cough is another hallmark symptom of IPF. This cough does not produce mucus and does not go away, even with typical cough medicines. The cough can be bothersome and may worsen over time. It can interfere with sleep, social activities, and overall quality of life.[1][3]

Extreme tiredness, or fatigue, is common in people with IPF. This is not just feeling tired after a busy day. It is a deep, persistent exhaustion that does not improve with rest. Fatigue can make it difficult to carry out daily tasks and can affect a person’s mood and mental health.[3]

Unintended weight loss can occur as the disease progresses. This may happen because breathing requires more effort, which burns more energy, or because people with IPF may feel too tired or breathless to eat properly.[3]

Aching muscles and joints are sometimes reported by people with IPF. The reasons for this are not entirely clear, but it may be related to the body’s overall response to chronic illness and reduced activity levels.[3]

Clubbing is a physical sign that can develop in people with IPF. This refers to a widening and rounding of the tips of the fingers or toes. The nails may also become curved and dome-shaped. Clubbing happens because of low oxygen levels in the blood over a long period. It is a visible sign that the lungs are not working properly.[1][3]

Some people with IPF may notice changes in the color of their skin, especially around the lips, eyes, or nails. The skin may take on a bluish, gray, or white tint, a condition called cyanosis. This happens when there is not enough oxygen in the blood.[6]

Many people with IPF also experience what are known as acute exacerbations. These are episodes where symptoms suddenly become much worse over a period of days or weeks. Exacerbations can be triggered by infections or other factors, but often there is no obvious cause. They can be life-threatening and require immediate medical attention.[1]

Preventing Idiopathic Pulmonary Fibrosis

Because the exact cause of IPF is not known, there is no guaranteed way to prevent the disease. However, there are steps people can take to reduce their risk or protect their lungs from further damage if they have already been diagnosed.[1]

Quitting smoking is the single most important action a person can take to protect their lungs. Smoking damages the delicate tissues of the lungs and increases the risk of developing IPF. For people who already have IPF, continuing to smoke can make the disease worse and speed up the progression of scarring. Even if someone has smoked for many years, quitting at any point can still benefit lung health.[4]

Avoiding exposure to harmful substances is another key preventive measure. People who work in industries where they are exposed to dusts from metals, wood, stone, or agricultural materials should use protective equipment such as masks and respirators. Limiting exposure to chemicals, fumes, and other lung irritants can help reduce the risk of lung damage.[4]

Staying up to date with vaccinations can help protect the lungs from infections that could worsen lung disease. People with IPF, or those at risk, should receive the annual flu vaccine and the one-time pneumococcal vaccine, which protects against pneumonia. These infections can be more serious in people with lung conditions and can lead to complications.[4][14]

Eating a healthy, balanced diet and staying physically active can support overall health and help the body cope with chronic illness. Regular exercise can improve lung function, strengthen muscles, and boost energy levels. Even gentle activities like walking or stretching can be beneficial for people with lung disease.[4]

People with a family history of IPF or other risk factors should talk to their doctor about monitoring their lung health. Early detection of lung problems can allow for earlier intervention and better management of symptoms.[7]

How IPF Affects the Lungs

To understand IPF, it helps to know how healthy lungs work. When you breathe in, air travels down your windpipe and into smaller tubes called bronchi, which branch out like a tree into even smaller tubes called bronchioles. At the end of these tiny tubes are clusters of air sacs called alveoli. The alveoli are surrounded by tiny blood vessels called capillaries. Oxygen from the air passes through the thin walls of the alveoli into the blood, while carbon dioxide, a waste product, moves from the blood into the alveoli to be breathed out.[1]

In IPF, the tissue surrounding the alveoli becomes damaged and thickened. This tissue, known as the interstitium, is normally very thin and flexible, allowing oxygen to pass through easily. When scarring occurs, the interstitium becomes thick, stiff, and less flexible. This makes it much harder for oxygen to move from the air into the bloodstream.[1]

As more and more scar tissue builds up, the lungs lose their ability to expand and contract properly. This is called reduced lung compliance. The lungs become stiff, like a dried sponge, instead of soft and elastic. This stiffness makes it difficult to take deep breaths and leads to the sensation of breathlessness.[6]

The scarring process in IPF is progressive and irreversible. Once scar tissue forms, it cannot be removed or turned back into healthy lung tissue. Over time, the scarring spreads, affecting larger and larger areas of the lungs. This reduces the total surface area available for gas exchange, meaning less oxygen can enter the blood.[1]

When the lungs cannot deliver enough oxygen to the bloodstream, this leads to a condition called hypoxemia, which means low oxygen levels in the blood. Hypoxemia can cause fatigue, confusion, and changes in skin color. If tissues throughout the body do not receive enough oxygen, this is called hypoxia, which can damage organs and lead to serious complications.[6]

The scarred lungs also have a hard time removing carbon dioxide, the waste gas produced by the body’s cells. If carbon dioxide builds up in the blood, it can lead to a condition called respiratory failure, where the lungs can no longer support normal breathing without help from machines.[1]

Because the lungs are working harder and less efficiently, the heart also has to work harder to pump blood through the lungs. This can lead to a condition called pulmonary hypertension, which means high blood pressure in the arteries of the lungs. Over time, pulmonary hypertension can strain the right side of the heart, potentially leading to heart failure.[1][6]

The changes in lung structure in IPF are complex and involve many different types of cells. Fibroblasts, the cells that produce scar tissue, become overactive and produce too much collagen, a protein that forms the structure of scar tissue. The immune system also plays a role, though the exact mechanisms are still being studied. There is also evidence of abnormal cell behavior, including the presence of unusual cells and problems with cell aging, known as cell senescence.[13]

⚠️ Important
Understanding how IPF affects your lungs can help you make sense of your symptoms and why certain treatments are recommended. The scarring process is irreversible, but treatments can slow it down and help you breathe more comfortably. Always discuss any new or worsening symptoms with your healthcare team, as early intervention can make a significant difference.

Ongoing Clinical Trials on Idiopathic pulmonary fibrosis

  • Study on Inhaled Phospholipid Fraction from Bovine Lung for Patients with Idiopathic Pulmonary Fibrosis

    Not yet recruiting

    1 1
    Investigated diseases:
    Germany
  • Study on the Effects of GSK3915393 for Patients with Idiopathic Pulmonary Fibrosis

    Not recruiting

    Investigated diseases:
    Investigated drugs:
    France Germany Italy The Netherlands Poland Spain
  • A study to evaluate the effectiveness and safety of admilparant in patients with idiopathic pulmonary fibrosis

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +9
  • Study on the Effects of CAL101 for Patients with Idiopathic Pulmonary Fibrosis

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Denmark France Italy The Netherlands Norway Romania +1
  • Study on the Safety and Effectiveness of Taladegib for Patients with Idiopathic Pulmonary Fibrosis

    Not recruiting

    Investigated diseases:
    Investigated drugs:
    Austria Belgium France Germany Ireland Italy
  • Study on BI 1839100 for Reducing Cough in Patients with Idiopathic or Progressive Pulmonary Fibrosis

    Not recruiting

    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +9
  • Study on the Effects of Inhaled Treprostinil for Patients with Idiopathic Pulmonary Fibrosis

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Denmark France Germany Italy The Netherlands +1
  • Study on BI 1819479 to Improve Lung Function in Patients with Idiopathic Pulmonary Fibrosis

    Not recruiting

    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +8
  • Study on the Effects and Safety of Buloxibutid for Patients with Idiopathic Pulmonary Fibrosis

    Not recruiting

    Investigated diseases:
    Investigated drugs:
    Austria Belgium Germany Greece Italy Poland
  • Study on the Effectiveness and Safety of LTP001 for Patients with Idiopathic Pulmonary Fibrosis

    Not recruiting

    Investigated diseases:
    Investigated drugs:
    Czechia Germany The Netherlands Poland

References

https://www.nhlbi.nih.gov/health/idiopathic-pulmonary-fibrosis

https://www.pulmonaryfibrosis.org/understanding-pff/types-of-pulmonary-fibrosis/idiopathic-pulmonary-fibrosis

https://www.mayoclinic.org/diseases-conditions/pulmonary-fibrosis/symptoms-causes/syc-20353690

https://www.nhs.uk/conditions/idiopathic-pulmonary-fibrosis/

https://www.lung.org/lung-health-diseases/lung-disease-lookup/idiopathic-pulmonary-fibrosis

https://my.clevelandclinic.org/health/diseases/10959-pulmonary-fibrosis

https://www.actionpf.org/information-support/idiopathic-pulmonary-fibrosis

https://en.wikipedia.org/wiki/Idiopathic_pulmonary_fibrosis

https://www.upmc.com/services/pulmonology/conditions/ipf

https://www.nhs.uk/conditions/idiopathic-pulmonary-fibrosis/treatment/

https://www.mayoclinic.org/diseases-conditions/pulmonary-fibrosis/diagnosis-treatment/drc-20353695

https://www.lung.org/lung-health-diseases/lung-disease-lookup/pulmonary-fibrosis/patients/how-is-pulmonary-fibrosis-treated/medications

https://pmc.ncbi.nlm.nih.gov/articles/PMC9060042/

https://emedicine.medscape.com/article/301226-treatment

https://www.pulmonaryfibrosis.org/understanding-pff/treatment-options/medications

https://news.vumc.org/2025/01/08/study-suggests-a-new-way-to-treat-incurable-lung-disease/

https://www.pulmonaryfibrosis.org/patients-caregivers/education-resources/maintain-your-health

https://www.lung.org/lung-health-diseases/lung-disease-lookup/pulmonary-fibrosis/patients/living-well-with-pulmonary-fibrosis/living-with-pulmonary

https://www.nhlbi.nih.gov/health/idiopathic-pulmonary-fibrosis/living-with

https://pfwarriors.com/5-secrets-from-patients-living-with-pulmonary-fibrosis/

https://www.nationaljewish.org/education/health-information/living-with-idiopathic-pulmonary-fibrosis

https://www.nhs.uk/conditions/idiopathic-pulmonary-fibrosis/treatment/

FAQ

Is idiopathic pulmonary fibrosis contagious?

No, IPF is not contagious. You cannot catch it from someone else, and you cannot pass it to others. It is not caused by a virus, bacteria, or any other infectious agent.

How long can someone live with idiopathic pulmonary fibrosis?

The progression of IPF varies greatly from person to person, and it is difficult to predict how long someone will live after diagnosis. Average life expectancy has historically been about three to five years, though this was based on studies done before newer treatments became available. Some people respond well to treatment and remain relatively stable for many years, while others experience rapid progression. Regular monitoring and treatment can help improve outcomes and quality of life.

Can IPF be cured?

There is currently no cure for IPF. The lung damage and scarring that occur cannot be reversed or repaired. However, treatments are available that can slow down the progression of the disease, help manage symptoms, and improve quality of life. For some people, a lung transplant may be an option and can significantly improve life expectancy.

What is an acute exacerbation of IPF?

An acute exacerbation is a sudden worsening of symptoms that happens over a period of days or weeks. During an exacerbation, breathing becomes much more difficult, and oxygen levels may drop. These episodes can be triggered by infections or other factors, but often there is no obvious cause. Acute exacerbations can be life-threatening and require immediate medical attention. They are more common in advanced stages of IPF.

What tests are used to diagnose idiopathic pulmonary fibrosis?

Diagnosing IPF involves multiple tests. These typically include breathing tests to measure how well your lungs work, blood tests, a chest X-ray, and a high-resolution CT scan to look at the lung tissue in detail. In some cases, a lung biopsy may be needed, where a small piece of lung tissue is removed and examined under a microscope. Doctors also check for and rule out other conditions that can cause similar symptoms.

🎯 Key takeaways

  • IPF is a progressive lung disease where scar tissue builds up around the air sacs, making breathing increasingly difficult, and the cause remains unknown.
  • The disease most commonly affects people in their 60s and 70s, with men being affected more often than women.
  • Smoking is one of the strongest risk factors for developing IPF, and quitting smoking is crucial for protecting lung health.
  • The most common symptoms are shortness of breath and a persistent dry cough, which worsen gradually over time.
  • There is currently no cure for IPF, but treatments like pirfenidone and nintedanib can slow disease progression and improve quality of life.
  • About 5 to 20 percent of people with IPF have a family history of the disease, suggesting genetic factors play a role.
  • Oxygen therapy, pulmonary rehabilitation, and lifestyle changes can help manage symptoms and keep people more active.
  • For some patients, a lung transplant can significantly improve life expectancy, though it is a major procedure with specific eligibility criteria.